Xi Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xi Zhao has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Meihui Tao
Department of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China
3 shared publications - Wei Yan
Department of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3 shared publications - Yu Fu
Department of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3 shared publications - Chaoyue Chen
Department of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People’s Republic of China
2 shared publications - Dean Tian
Department of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
1 shared publication - Jianhua Yi
Department of Infectious Disease, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
1 shared publication
Latest Publications
- Open Access
- 1 September 2025
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 18, 5115-5125
Low-Density Lipoprotein and High-Density Lipoprotein as Biomarkers for Inflammatory Bowel Disease Activity Assessment
Purpose: To explore the correlation of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) with inflammatory bowel disease activity and their value in predicting disease activity. Patients and methods: Clinical data of 490 adult IBD patients diagnosed in two IBD centers were collected, and 200 healthy people were served as controls. To evaluate the correlation of IDL and HDL with clinical and endoscopic activity of inflammatory bowel disease (IBD), and to explore the predictive value of them for disease activity. Results: In CD, there were differences in HDL, CRP and ESR levels (p< 0.001) among different disease activity groups. HDL levels were negatively correlated with HBI and CDEIS. In UC, there were differences in LDL, HDL, CRP and ESR levels among groups with different disease activities (p< 0.001). Both LDL and HDL levels were negatively correlated with Mayo clinical score and UCEIS (p< 0.001). The sensitivity of LDL for predicting moderate-severe UC was slightly higher than CRP (65.65% vs 60.31%). The specificity of HDL in predicting moderate-severe CD (65.85% vs 52.44%) and UC (87.34% vs 79.75%) was higher than CRP. Conclusion: In patients with IBD, serum levels of both LDL and HDL were significantly lower compared to healthy controls. These levels correlated with disease activity. Furthermore, LDL and HDL levels demonstrated potential utility in distinguishing patients with moderate-severe IBD and show promise as monitoring biomarkers for IBD.
- 1 September 2025
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 18, 5115-5125
Open AccessLow-Density Lipoprotein and High-Density Lipoprotein as Biomarkers for Inflammatory Bowel Disease Activity Assessment
Purpose: To explore the correlation of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) with inflammatory bowel disease activity and their value in predicting disease activity. Patients and methods: Clinical data of 490 adult IBD patients diagnosed in two IBD centers were collected, and 200 healthy people were served as controls. To evaluate the correlation of IDL and HDL with clinical and endoscopic activity of inflammatory bowel disease (IBD), and to explore the predictive value of them for disease activity. Results: In CD, there were differences in HDL, CRP and ESR levels (p< 0.001) among different disease activity groups. HDL levels were negatively correlated with HBI and CDEIS. In UC, there were differences in LDL, HDL, CRP and ESR levels among groups with different disease activities (p< 0.001). Both LDL and HDL levels were negatively correlated with Mayo clinical score and UCEIS (p< 0.001). The sensitivity of LDL for predicting moderate-severe UC was slightly higher than CRP (65.65% vs 60.31%). The specificity of HDL in predicting moderate-severe CD (65.85% vs 52.44%) and UC (87.34% vs 79.75%) was higher than CRP. Conclusion: In patients with IBD, serum levels of both LDL and HDL were significantly lower compared to healthy controls. These levels correlated with disease activity. Furthermore, LDL and HDL levels demonstrated potential utility in distinguishing patients with moderate-severe IBD and show promise as monitoring biomarkers for IBD.
- Open Access
- 1 September 2021
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 14, 3699-3710
Hypoalbuminemia – An Indicator of the Severity and Prognosis of COVID-19 Patients: A Multicentre Retrospective Analysis
Background: Hypoalbuminemia has been reported in COVID-19 patients. Exploring the influencing factors and possible adverse consequences of albumin reduction may provide some guidance for the treatment of COVID-19 patients. Methods: In this multicentre retrospective study, we collected information including demographics, comorbidities, clinical symptoms, complications, laboratory tests, treatment, and outcomes of patients diagnosed with COVID-19 from three hospitals in Wuhan, China. We compared the indexes between patients with hypoalbuminemia and normal albumin. Regression model was used to evaluate various influencing factors of patients with hypoalbuminemia and their relationship with clinical outcomes. We also compared the changes of particular laboratory indexes in patients with hypoalbuminemia before and after enteral nutrition therapy. Results: A total of 482 patients were enrolled in the study. About 53.7% patients developed hypoalbuminemia during admission. Patients with hypoalbuminemia were older, had a higher proportion of combined diabetes mellitus, fever, dyspnea, and natriuresis, and had a relatively poorer prognosis than patients with normal albumin. Patients with hypoalbuminemia had higher levels of CRP, leukocytes, ALT, AST, total bilirubin, ALP, GGT, LDH, creatine kinase, D-dimer, globulin, and lower levels of lymphocytes and eosinophils. Severe, older, anorexia, elevated CRP, and decreased lymphocytes were the independent predictors for decreased albumin in COVID-19 patients. In addition, decreased albumin is correlated with adverse outcomes. Nutritional support therapy to correct serum albumin may improve patient outcomes. Conclusion: COVID-19 patients with hypoalbuminemia tend to have more severe clinical manifestations and more abnormal biochemical tests, which may result in poorer clinical outcomes. Nutritional support therapy may improve the clinical outcome of these patients.
- 1 September 2021
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 14, 3699-3710
Open AccessHypoalbuminemia – An Indicator of the Severity and Prognosis of COVID-19 Patients: A Multicentre Retrospective Analysis
Background: Hypoalbuminemia has been reported in COVID-19 patients. Exploring the influencing factors and possible adverse consequences of albumin reduction may provide some guidance for the treatment of COVID-19 patients. Methods: In this multicentre retrospective study, we collected information including demographics, comorbidities, clinical symptoms, complications, laboratory tests, treatment, and outcomes of patients diagnosed with COVID-19 from three hospitals in Wuhan, China. We compared the indexes between patients with hypoalbuminemia and normal albumin. Regression model was used to evaluate various influencing factors of patients with hypoalbuminemia and their relationship with clinical outcomes. We also compared the changes of particular laboratory indexes in patients with hypoalbuminemia before and after enteral nutrition therapy. Results: A total of 482 patients were enrolled in the study. About 53.7% patients developed hypoalbuminemia during admission. Patients with hypoalbuminemia were older, had a higher proportion of combined diabetes mellitus, fever, dyspnea, and natriuresis, and had a relatively poorer prognosis than patients with normal albumin. Patients with hypoalbuminemia had higher levels of CRP, leukocytes, ALT, AST, total bilirubin, ALP, GGT, LDH, creatine kinase, D-dimer, globulin, and lower levels of lymphocytes and eosinophils. Severe, older, anorexia, elevated CRP, and decreased lymphocytes were the independent predictors for decreased albumin in COVID-19 patients. In addition, decreased albumin is correlated with adverse outcomes. Nutritional support therapy to correct serum albumin may improve patient outcomes. Conclusion: COVID-19 patients with hypoalbuminemia tend to have more severe clinical manifestations and more abnormal biochemical tests, which may result in poorer clinical outcomes. Nutritional support therapy may improve the clinical outcome of these patients.
- Open Access
- 30 June 2020
- Published by Wolters Kluwer Health in Hepatology
- Vol. 73 (4) , 1509-1520
Clinical Features of Patients Infected With Coronavirus Disease 2019 With Elevated Liver Biochemistries: A Multicenter, Retrospective Study
Background and Aims: In December 2019, an outbreak of coronavirus disease 2019 (COVID‐19) emerged in Wuhan, China. Although it has been reported that some patients with COVID‐19 showed elevated liver biochemistries, there are few studies regarding the clinical features and prognosis of these patients. Approach and Results: In this multicenter, retrospective study, we collected data on laboratory‐confirmed patients with COVID‐19 from three hospitals in Wuhan, China, who died or were discharged between February 1, 2020, and February 20, 2020. Data on demographics, comorbidities, clinical symptoms, laboratory examinations on admission, complications, treatment, and outcome were collected. A total of 482 patients were enrolled in this study. Of those, 142 (29.5%) patients showed abnormal liver biochemistries on admission, and patients with elevated alanine aminotransferase, aspartate aminotransferase (AST), and total bilirubin (TBIL) accounted for 67.6%, 69.0%, and 16.2%, respectively. Those with abnormal liver biochemistries showed higher percentages of severe cases and comorbidities and were more likely to have dyspnea, chest distress or pain, and increased hemoglobin (Hb) on admission. Higher rates of complications and mortality and worse recovery when discharged were observed in patients with abnormal AST or TBIL. Multivariable regression analysis showed that chest distress or pain (odds ratio [OR], 1.765; P = 0.018), dyspnea (OR, 2.495; P = 0.001), elevated C‐reactive protein level (OR, 1.007; P = 0.008), elevated white blood count (OR, 1.139; P = 0.013), and elevated Hb concentration (OR, 1.024; P = 0.001) were independent factors associated with elevated liver biochemistries in patients with COVID‐19. Conclusions: Elevated liver biochemistries were common in patients with COVID‐19. Patients with hypoxia or severe inflammation are more likely to experience increased liver biochemistries on admission. Those with abnormal AST or TBIL on admission are more likely to suffer from severe complications and death.
- 30 June 2020
- Published by Wolters Kluwer Health in Hepatology
- Vol. 73 (4) , 1509-1520
Open AccessClinical Features of Patients Infected With Coronavirus Disease 2019 With Elevated Liver Biochemistries: A Multicenter, Retrospective Study
Background and Aims: In December 2019, an outbreak of coronavirus disease 2019 (COVID‐19) emerged in Wuhan, China. Although it has been reported that some patients with COVID‐19 showed elevated liver biochemistries, there are few studies regarding the clinical features and prognosis of these patients. Approach and Results: In this multicenter, retrospective study, we collected data on laboratory‐confirmed patients with COVID‐19 from three hospitals in Wuhan, China, who died or were discharged between February 1, 2020, and February 20, 2020. Data on demographics, comorbidities, clinical symptoms, laboratory examinations on admission, complications, treatment, and outcome were collected. A total of 482 patients were enrolled in this study. Of those, 142 (29.5%) patients showed abnormal liver biochemistries on admission, and patients with elevated alanine aminotransferase, aspartate aminotransferase (AST), and total bilirubin (TBIL) accounted for 67.6%, 69.0%, and 16.2%, respectively. Those with abnormal liver biochemistries showed higher percentages of severe cases and comorbidities and were more likely to have dyspnea, chest distress or pain, and increased hemoglobin (Hb) on admission. Higher rates of complications and mortality and worse recovery when discharged were observed in patients with abnormal AST or TBIL. Multivariable regression analysis showed that chest distress or pain (odds ratio [OR], 1.765; P = 0.018), dyspnea (OR, 2.495; P = 0.001), elevated C‐reactive protein level (OR, 1.007; P = 0.008), elevated white blood count (OR, 1.139; P = 0.013), and elevated Hb concentration (OR, 1.024; P = 0.001) were independent factors associated with elevated liver biochemistries in patients with COVID‐19. Conclusions: Elevated liver biochemistries were common in patients with COVID‐19. Patients with hypoxia or severe inflammation are more likely to experience increased liver biochemistries on admission. Those with abnormal AST or TBIL on admission are more likely to suffer from severe complications and death.